For example, the differentiation among AChR and MuSK antibody positive patients has important implications for therapy, since the latter can present with adverse effects when treated with AChE inhibitors, a common first line AChR-MG treatment, thymectomy, or the use of complement inhibitors does not appear to be beneficial to them (129). The gene discussed is MUSK; the disease is myasthenia gravis.